FOLLICULAR LYMPHOMA ( FL)

This study tests a combination of two treatments—an immune cell therapy (relmacabtagene autoleucel) and an immunotherapy drug (sintilimab)—in 30 adults with relapsed or refractory B-cell lymphoma (including diffuse large B-cell, mantle cell, and follicular lymphoma). The goal is …

This study tests a new drug called MDX2003 in adults with several types of B-cell lymphoma (like DLBCL or follicular lymphoma) that have returned or stopped responding to at least two prior treatments. The main goals are to find the safest dose and check if the drug can shrink tu…

This study tests a new treatment called Talikabtagene autoleucel (NexCAR19) for adults with certain blood cancers that have come back or not responded to standard therapy. The treatment uses a patient's own immune cells, which are modified in a lab to better recognize and attack …

This early-phase study tests a new cell therapy called CT1182 in 24 adults with B-cell non-Hodgkin lymphoma that has come back or not responded to treatment. The main goals are to check safety, find the best dose, and see how well it shrinks tumors. Researchers will monitor side …

This study tests a new drug, odronextamab, for people with untreated follicular lymphoma, a type of blood cancer. About 822 participants will receive either the new drug or standard treatment (rituximab plus chemotherapy) to compare safety and effectiveness. The goal is to see if…

This early-phase study tests a new treatment called GF-CART01 for adults aged 18-70 with B-cell blood cancers (like certain lymphomas) that have come back or not responded to standard treatments. The therapy uses a patient's own immune cells, modified to target two markers (CD20 …

This early-stage study tests an experimental drug called mevrometostat in adults with certain advanced cancers that have stopped responding to standard treatments. The study is currently enrolling men with castration-resistant prostate cancer. Participants receive the drug by mou…

This study tests whether adding the experimental drug epcoritamab to standard treatments (rituximab and lenalidomide) works better than usual chemo for people with untreated follicular lymphoma, a slow-growing blood cancer. About 1,095 adults will be randomly assigned to differen…

This study tests a new drug called surovatamig in 240 adults with B-cell non-Hodgkin lymphoma that has come back or not responded to at least two prior treatments. The goal is to see if the drug can shrink or eliminate tumors. Participants receive the drug alone, and researchers …

This early-stage study tests a new drug called NX-2127 in adults with certain blood cancers (like CLL or lymphoma) that have returned or not improved after other treatments. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors. About …

This study tests an experimental drug called NX-5948 in adults with certain blood cancers (like CLL or lymphoma) that have come back or stopped responding to treatment. The drug works by breaking down a protein that helps cancer cells grow. The main goals are to find a safe dose …

This early-phase study tests a new drug called LTZ-301 in 42 adults with certain types of non-Hodgkin lymphoma that have not responded to at least two prior treatments. The main goal is to check the drug's safety and find the right dose. Researchers will also look for signs that …

This study is collecting blood and leftover tissue samples from 550 people with acute myeloid leukemia or follicular lymphoma. Researchers will analyze the samples to find genetic markers that may predict how well treatments work or why they stop working. The goal is to better un…

This study is a registry that will follow about 2950 adults in Germany with certain blood cancers (like CLL, DLBCL, and others). Researchers will collect information on the treatments people receive, how their disease progresses, and their quality of life. No new treatments are g…